Skip to main content
Top
Published in: Critical Care 1/2017

Open Access 01-12-2017 | Research

Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction

Authors: Matthias Klingele, Theresa Stadler, Danilo Fliser, Timo Speer, Heinrich V. Groesdonk, Alexander Raddatz

Published in: Critical Care | Issue 1/2017

Login to get access

Abstract

Background

As of 2009, anticoagulation with citrate was standard practice in continuous renal replacement therapy (CRRT) for critically ill patients at the University Medical Centre of Saarland, Germany. Partial hepatic metabolism of citrate means accumulation may occur during CRRT in critically ill patients with impaired liver function. The aim of this study was to evaluate the actual influence of hepatic function on citrate-associated complications during long-term CRRT.

Methods

In a retrospective study conducted between January 2009 and November 2012, all cases of dialysis therapy performed in the interdisciplinary surgical intensive care unit were analysed. Inclusion criteria were CRRT and regional anticoagulation with citrate, pronounced liver dysfunction, and pathologically reduced indocyanine green plasma disappearance rate (ICG-PDR).

Results

A total of 1339 CRRTs were performed in 69 critically ill patients with liver failure. At admission, the mean Model for End-stage Liver Disease score was 19.2, and the mean ICG-PDR was 9.8%. Eight patients were treated with liver replacement therapy, and 30 underwent transplants. The mortality rate was 40%. The mean duration of dialysis was 19.4 days, and the circuit patency was 62.2 h. Accumulation of citrate was detected indirectly by total serum calcium/ionised serum calcium (tCa/iCa) ratio > 2.4. This was noted in 16 patients (23.2%). Dialysis had not to be discontinued for metabolic disorder or accumulation of citrate in any case. In 26% of cases, metabolic alkalosis occurred with pH > 7.5. Interestingly, no correlation between citrate accumulation and liver function parameters was detected. Moreover, most standard laboratory liver function parameters showed poor predictive capabilities for accumulation of citrate.

Conclusions

Our findings indicate that extra-hepatic metabolism of citrate seems to exist, avoiding in most cases citrate accumulation in critically ill patients despite impaired liver function. Because the citric acid cycle is oxygen-dependent, disturbed microcirculation would result in inadequate citrate metabolism. Raising the tCa/iCa ratio would therefore be an indicator of severity of illness and mortality rather than of liver failure. However, further studies are warranted for confirmation.
Literature
1.
go back to reference Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the problem? Crit Care Med. 2008;36(4 Suppl):S146–51.CrossRef Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the problem? Crit Care Med. 2008;36(4 Suppl):S146–51.CrossRef
2.
go back to reference Ostermann M, Dickie H, Tovey L, Treacher D. Heparin algorithm for anticoagulation during continuous renal replacement therapy. Crit Care. 2010;14(3):419.CrossRef Ostermann M, Dickie H, Tovey L, Treacher D. Heparin algorithm for anticoagulation during continuous renal replacement therapy. Crit Care. 2010;14(3):419.CrossRef
3.
go back to reference Schultheiss C, Saugel B, Phillip V, Thies P, Noe S, Mayr U, Haller B, Einwachter H, Schmid RM, Huber W. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care. 2012;16(4):R162.CrossRef Schultheiss C, Saugel B, Phillip V, Thies P, Noe S, Mayr U, Haller B, Einwachter H, Schmid RM, Huber W. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care. 2012;16(4):R162.CrossRef
4.
go back to reference Chappell JB. The oxidation of citrate, isocitrate and cis-aconitate by isolated mitochondria. Biochem J. 1964;90(2):225–37.CrossRef Chappell JB. The oxidation of citrate, isocitrate and cis-aconitate by isolated mitochondria. Biochem J. 1964;90(2):225–37.CrossRef
5.
go back to reference Wexler IB, Pincus JB, Natelson S, Lugovoy JK. The fate of citrate in erythroblastotic infants treated with exchange transfusion. J Clin Invest. 1949;28(3):474–81.CrossRef Wexler IB, Pincus JB, Natelson S, Lugovoy JK. The fate of citrate in erythroblastotic infants treated with exchange transfusion. J Clin Invest. 1949;28(3):474–81.CrossRef
6.
go back to reference Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, Gangl A. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003;31(10):2450–5.CrossRef Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, Gangl A. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003;31(10):2450–5.CrossRef
7.
go back to reference Leung AK, Shum HP, Chan KC, Chan SC, Lai KY, Yan WW. A retrospective review of the use of regional citrate anticoagulation in continuous venovenous hemofiltration for critically ill patients. Crit Care Res Pract. 2013;2013:349512.PubMedPubMedCentral Leung AK, Shum HP, Chan KC, Chan SC, Lai KY, Yan WW. A retrospective review of the use of regional citrate anticoagulation in continuous venovenous hemofiltration for critically ill patients. Crit Care Res Pract. 2013;2013:349512.PubMedPubMedCentral
8.
go back to reference Saner FH, Treckmann JW, Geis A, Losch C, Witzke O, Canbay A, Herget-Rosenthal S, Kribben A, Paul A, Feldkamp T. Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring post-operative renal replacement therapy. Nephrol Dial Transplant. 2012;27(4):1651–7.CrossRef Saner FH, Treckmann JW, Geis A, Losch C, Witzke O, Canbay A, Herget-Rosenthal S, Kribben A, Paul A, Feldkamp T. Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring post-operative renal replacement therapy. Nephrol Dial Transplant. 2012;27(4):1651–7.CrossRef
9.
go back to reference Slowinski T, Morgera S, Joannidis M, Henneberg T, Stocker R, Helset E, Andersson K, Wehner M, Kozik-Jaromin J, Brett S, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care. 2015;19:349.CrossRef Slowinski T, Morgera S, Joannidis M, Henneberg T, Stocker R, Helset E, Andersson K, Wehner M, Kozik-Jaromin J, Brett S, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care. 2015;19:349.CrossRef
10.
go back to reference Halle BM, Poulsen TD, Pedersen HP. Indocyanine green plasma disappearance rate as dynamic liver function test in critically ill patients. Acta Anaesthesiol Scand. 2014;58(10):1214–9.CrossRef Halle BM, Poulsen TD, Pedersen HP. Indocyanine green plasma disappearance rate as dynamic liver function test in critically ill patients. Acta Anaesthesiol Scand. 2014;58(10):1214–9.CrossRef
11.
go back to reference Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest. 2002;122(5):1715–20.CrossRef Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest. 2002;122(5):1715–20.CrossRef
12.
go back to reference Stauber RE, Wagner D, Stadlbauer V, Palma S, Gurakuqi G, Kniepeiss D, Iberer F, Smolle KH, Haas J, Trauner M. Evaluation of indocyanine green clearance and model for end-stage liver disease for estimation of short-term prognosis in decompensated cirrhosis. Liver Int. 2009;29(10):1516–20.CrossRef Stauber RE, Wagner D, Stadlbauer V, Palma S, Gurakuqi G, Kniepeiss D, Iberer F, Smolle KH, Haas J, Trauner M. Evaluation of indocyanine green clearance and model for end-stage liver disease for estimation of short-term prognosis in decompensated cirrhosis. Liver Int. 2009;29(10):1516–20.CrossRef
13.
go back to reference Calatzis A, Toepfer M, Schramm W, Spannagl M, Schiffl H. Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation. Nephron. 2001;89(2):233–6.CrossRef Calatzis A, Toepfer M, Schramm W, Spannagl M, Schiffl H. Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation. Nephron. 2001;89(2):233–6.CrossRef
14.
go back to reference Hetzel GR, Taskaya G, Sucker C, Hennersdorf M, Grabensee B, Schmitz M. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis. 2006;48(5):806–11.CrossRef Hetzel GR, Taskaya G, Sucker C, Hennersdorf M, Grabensee B, Schmitz M. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis. 2006;48(5):806–11.CrossRef
15.
go back to reference Apsner R, Schwarzenhofer M, Derfler K, Zauner C, Ratheiser K, Kranz A. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr. 1997;109(4):123–7.PubMed Apsner R, Schwarzenhofer M, Derfler K, Zauner C, Ratheiser K, Kranz A. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr. 1997;109(4):123–7.PubMed
16.
go back to reference Meier-Kriesche HU, Finkel KW, Gitomer JJ, DuBose Jr TD. Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. Am J Kidney Dis. 1999;33(4), e8.CrossRef Meier-Kriesche HU, Finkel KW, Gitomer JJ, DuBose Jr TD. Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. Am J Kidney Dis. 1999;33(4), e8.CrossRef
17.
go back to reference Diaz J, Acosta F, Parrilla P, Sansano T, Bento M, Cura S, Contreras RF, Belmonte JG, Bueno FS, Robles R, et al. Citrate intoxication and blood concentration of ionized calcium in liver transplantation. Transplant Proc. 1994;26(6):3669–70.PubMed Diaz J, Acosta F, Parrilla P, Sansano T, Bento M, Cura S, Contreras RF, Belmonte JG, Bueno FS, Robles R, et al. Citrate intoxication and blood concentration of ionized calcium in liver transplantation. Transplant Proc. 1994;26(6):3669–70.PubMed
18.
go back to reference Marquez J, Martin D, Virji MA, Kang YG, Warty VS, Shaw Jr B, Sassano JJ, Waterman P, Winter PM, Pinsky MR. Cardiovascular depression secondary to ionic hypocalcemia during hepatic transplantation in humans. Anesthesiology. 1986;65(5):457–61.CrossRef Marquez J, Martin D, Virji MA, Kang YG, Warty VS, Shaw Jr B, Sassano JJ, Waterman P, Winter PM, Pinsky MR. Cardiovascular depression secondary to ionic hypocalcemia during hepatic transplantation in humans. Anesthesiology. 1986;65(5):457–61.CrossRef
19.
go back to reference Bakker AJ, Boerma EC, Keidel H, Kingma P, van der Voort PH. Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clin Chem Lab Med. 2006;44(8):962–6.CrossRef Bakker AJ, Boerma EC, Keidel H, Kingma P, van der Voort PH. Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clin Chem Lab Med. 2006;44(8):962–6.CrossRef
20.
go back to reference Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med. 2001;29(4):748–52.CrossRef Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med. 2001;29(4):748–52.CrossRef
21.
go back to reference Link A, Klingele M, Speer T, Rbah R, Poss J, Lerner-Graber A, Fliser D, Bohm M. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. Crit Care. 2012;16(3):R97.CrossRef Link A, Klingele M, Speer T, Rbah R, Poss J, Lerner-Graber A, Fliser D, Bohm M. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. Crit Care. 2012;16(3):R97.CrossRef
22.
go back to reference Faybik P, Hetz H, Mitterer G, Krenn CG, Schiefer J, Funk GC, Bacher A. Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med. 2011;39(2):273–9.CrossRef Faybik P, Hetz H, Mitterer G, Krenn CG, Schiefer J, Funk GC, Bacher A. Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med. 2011;39(2):273–9.CrossRef
23.
go back to reference Meijers B, Laleman W, Vermeersch P, Nevens F, Wilmer A, Evenepoel P. A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System. Crit Care. 2012;16(1):R20.CrossRef Meijers B, Laleman W, Vermeersch P, Nevens F, Wilmer A, Evenepoel P. A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System. Crit Care. 2012;16(1):R20.CrossRef
24.
go back to reference Sponholz C, Settmacher U, Bauer M, Kortgen A. Regional citrate anticoagulation for continuous renal replacement therapy in the perioperative care of liver transplant recipients: a single center experience. Ther Apher Dial. 2015;19(1):8–15.CrossRef Sponholz C, Settmacher U, Bauer M, Kortgen A. Regional citrate anticoagulation for continuous renal replacement therapy in the perioperative care of liver transplant recipients: a single center experience. Ther Apher Dial. 2015;19(1):8–15.CrossRef
25.
go back to reference Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37(2):545–52.CrossRef Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37(2):545–52.CrossRef
26.
go back to reference Lahmer T, Messer M, Rasch S, Beitz A, Schnappauf C, Schmid RM, Huber W. Sustained low-efficiency dialysis with regional citrate anticoagulation in medical intensive care unit patients with liver failure: a prospective study. J Crit Care. 2015;30(5):1096–100.CrossRef Lahmer T, Messer M, Rasch S, Beitz A, Schnappauf C, Schmid RM, Huber W. Sustained low-efficiency dialysis with regional citrate anticoagulation in medical intensive care unit patients with liver failure: a prospective study. J Crit Care. 2015;30(5):1096–100.CrossRef
27.
go back to reference Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30(2):260–5.CrossRef Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30(2):260–5.CrossRef
28.
go back to reference Brophy PD, Somers MJ, Baum MA, Symons JM, McAfee N, Fortenberry JD, Rogers K, Barnett J, Blowey D, Baker C, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant. 2005;20(7):1416–21.CrossRef Brophy PD, Somers MJ, Baum MA, Symons JM, McAfee N, Fortenberry JD, Rogers K, Barnett J, Blowey D, Baker C, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant. 2005;20(7):1416–21.CrossRef
29.
go back to reference Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus. 2009;2(6):439–47.PubMedPubMedCentral Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus. 2009;2(6):439–47.PubMedPubMedCentral
30.
go back to reference Morgera S, Scholle C, Voss G, Haase M, Vargas-Hein O, Krausch D, Melzer C, Rosseau S, Zuckermann-Becker H, Neumayer HH. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract. 2004;97(4):c131–6.CrossRef Morgera S, Scholle C, Voss G, Haase M, Vargas-Hein O, Krausch D, Melzer C, Rosseau S, Zuckermann-Becker H, Neumayer HH. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract. 2004;97(4):c131–6.CrossRef
31.
go back to reference Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38(5):976–81.CrossRef Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38(5):976–81.CrossRef
32.
go back to reference Tan JN, Haroon SW, Mukhopadhyay A, Lau T, Murali TM, Phua J, Tan ZY, Lee N, Chua HR. Hyperlactatemia Predicts Citrate Intolerance With Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy. J Intensive Care Med. 2017. doi:10.1177/0885066617701068. CrossRef Tan JN, Haroon SW, Mukhopadhyay A, Lau T, Murali TM, Phua J, Tan ZY, Lee N, Chua HR. Hyperlactatemia Predicts Citrate Intolerance With Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy. J Intensive Care Med. 2017. doi:10.​1177/​0885066617701068​. CrossRef
33.
go back to reference Khadzhynov D, Dahlinger A, Schelter C, Peters H, Kindgen-Milles D, Budde K, Lehner LJ, Halleck F, Staeck O, Slowinski T. Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation. Crit Care Med. 2017;45(9):e941–6.CrossRef Khadzhynov D, Dahlinger A, Schelter C, Peters H, Kindgen-Milles D, Budde K, Lehner LJ, Halleck F, Staeck O, Slowinski T. Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation. Crit Care Med. 2017;45(9):e941–6.CrossRef
34.
go back to reference Malbrain ML, Viaene D, Kortgen A, De Laet I, Dits H, Van Regenmortel N, Schoonheydt K, Bauer M. Relationship between intra-abdominal pressure and indocyanine green plasma disappearance rate: hepatic perfusion may be impaired in critically ill patients with intra-abdominal hypertension. Ann Intensive Care. 2012;2 Suppl 1:S19.CrossRef Malbrain ML, Viaene D, Kortgen A, De Laet I, Dits H, Van Regenmortel N, Schoonheydt K, Bauer M. Relationship between intra-abdominal pressure and indocyanine green plasma disappearance rate: hepatic perfusion may be impaired in critically ill patients with intra-abdominal hypertension. Ann Intensive Care. 2012;2 Suppl 1:S19.CrossRef
Metadata
Title
Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
Authors
Matthias Klingele
Theresa Stadler
Danilo Fliser
Timo Speer
Heinrich V. Groesdonk
Alexander Raddatz
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2017
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-017-1870-3

Other articles of this Issue 1/2017

Critical Care 1/2017 Go to the issue